PTCT
PTC Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website cbio.com
- Employees(FY) 1402
- ISIN US69366J2006
Performance
-1.09%
1W
+17.65%
1M
+18.66%
3M
+63.61%
6M
+15.35%
YTD
-42.77%
1Y
Profile
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Investment Analysis Report: PTCT
Overview
In this investment analysis report, we will delve into the financial performance and health of PTCT, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial statements over the past three years, including balance sheets, inco...
Technical Analysis of PTCT 2024-05-03
Overview:
In analyzing the technical indicators for PTCT over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Indicators:
- Moving Averages (MA): The 5-day MA has been consistently rising, indicating a bulli...
Recent News & Updates
- 2024-05-02 08:00
- 2024-05-01 20:00
- 2024-05-01 14:45
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72(Investor's Business Daily)
- 2024-04-30 12:25
- 2024-04-29 06:11
- 2024-04-28 09:14
- 2024-04-27 09:12
PTC Therapeutics First Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-04-26 15:57
- 2024-04-26 11:16
- 2024-04-26 07:11
Q1 2024 PTC Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-04-26 03:35
- 2024-04-25 20:00
- 2024-04-25 17:39
- 2024-04-25 16:53
PTC Therapeutics: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-04-25 16:05
- 2024-04-25 08:56
- 2024-04-25 08:00
- 2024-04-25 04:05
- 2024-04-23 16:30
- 2024-04-23 04:30
- 2024-04-18 10:01
- 2024-04-17 22:01
- 2024-04-11 08:00
- 2024-04-10 20:00
- 2024-03-28 08:30
- 2024-03-27 20:30
- 2024-03-25 10:00
A Comprehensive Look at Sarepta's Growth and Innovation(GuruFocus.com)
- 2024-03-21 10:01
- 2024-03-20 14:00
- 2024-03-20 02:00
Page 1 of 6
previousnext